Germany says only Pfizer COVID jab should be used in under 30sGermany’s vaccination advisory committee has recommended that people aged under 30 should only be offered Pfizer/BioNTech’s COVID-19 vaccine Share XGermany says only Pfizer COVID jab should be used in under 30shttps://pharmaphorum.com/news/germany-says-only-pfizer-covid-jab-should-be-used-in-under-30s/
Germany confirms booster COVID jabs will start in SeptemberGermany’s health ministry has said it will start offering booster COVID-19 vaccines to vulnerable people from next month, Share XGermany confirms booster COVID jabs will start in Septemberhttps://pharmaphorum.com/news/germany-confirms-booster-covid-jabs-will-start-in-september/
Study finds Germany trails Spain and the US in digital healthGermany is lagging behind other countries in the adoption of digital health, including Spain and the US, according Share XStudy finds Germany trails Spain and the US in digital healthhttps://pharmaphorum.com/news/study-finds-germany-trails-spain-and-the-us-in-digital-health/
Healthcare bills to pay? Let hi.health pick up the tabJust over a year ago, hi.health launched an app that takes the legwork out of submitting reimbursement claims Share XHealthcare bills to pay? Let hi.health pick up the tabhttps://pharmaphorum.com/news/healthcare-bills-to-pay-let-hi-health-pick-up-the-tab/
Germany backtracks on AZ COVID vaccine age restrictionGermany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing Share XGermany backtracks on AZ COVID vaccine age restrictionhttps://pharmaphorum.com/news/germany-backtracks-on-az-covid-vaccine-age-restriction/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
AZ COVID jab efficacy debate is hindering EU’s vaccine driveThe spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks Share XAZ COVID jab efficacy debate is hindering EU’s vaccine drivehttps://pharmaphorum.com/news/az-covid-jab-efficacy-debate-is-hindering-eus-vaccine-drive/
Assessing the impact of prevalence on pricing of rare disease drugs in GermanyIn this first article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discuss Share XAssessing the impact of prevalence on pricing of rare disease drugs in Germanyhttps://pharmaphorum.com/views-analysis-market-access/assessing-pricing-of-rare-disease-drugs-in-germany/
BioNTech, CureVac claim bulk of Germany’s €750m COVID-19 vaccines fundIn May, Germany pledged to provide up to €750 million ($889 million) in funding to support vaccines against Share XBioNTech, CureVac claim bulk of Germany’s €750m COVID-19 vaccines fundhttps://pharmaphorum.com/news/biontech-curevac-claim-bulk-of-germanys-e750m-covid-19-vaccines-fund/
